Regeneron 73% response in ovarian cancer study, plans registrational cohort and Phase 3

 

Regeneron reports 73% response rate in early ubamatamab study in low‑grade serous ovarian cancer, plans registrational cohort and Phase 3

• Regeneron and Sanofi expand immunology alliance for four long-acting antibodies, adding $1B upfront and up to $7B in milestones.
• Alliance adopts 50:50 global cost and profit-sharing structure for the four new antibodies.
• Expanded collaboration also settles prior litigation between Regeneron and Sanofi.
• Phase 2 COURAGE data show trevogrumab preserves muscle mass during GLP-1-induced weight loss.
• Regeneron plans a new Phase 2 trial of trevogrumab in older adults with obesity and low muscle mass.
• Argus upgrades Regeneron to Buy from Hold with an $850 target, citing recent share pullback as attractive entry.

https://finviz.com/stock?t=REGN&p=d